In 2015, China introduced a series of reform measures in the field of medicine and health, covering a wide range of areas, including both the pharmaceutical industry and the medical and health product industries. These policies have to some extent affected the development of the industry. So, what major events will happen in the pharmaceutical industry in 2016, the first year of the 13th Five Year Plan?
　　
The policies for medicine, healthcare, and hygiene in 2015 are endless, and many pharmaceutical companies are not even aware of some policies introduced at the national, ministerial, and provincial levels. Even the author, who has long been concerned about industry policies, cannot recite all the numerous policy documents of 2015, and can only remember some key and influential policies.
　　
Why are the policies of the pharmaceutical, medical, and healthcare industries mentioned together? Because the policies of these three industries are interdependent, it is difficult to determine which policies are aimed at one industry without affecting other industries. For example, the Sanming Policy currently implemented by medical institutions should be a healthcare reform policy for medical institutions, but it also involves the issue of drug sales; For example, the promulgation of the New Advertising Law has caused many pharmaceutical, medical, and healthcare companies such as Harbin Pharmaceutical and Renhe, which use advertising as a means of operation, to lose their accustomed business motivation.
　　
Therefore, considering the author's clumsiness and inability to distinguish between various policy boundaries, we have to summarize, evaluate, and analyze them in a systematic manner. The main purpose is to enable everyone to look back at the various policies of 2015, which were shrouded in smoke, in order to clarify their origins and directions, and make early plans for the development of pharmaceutical enterprises.
　　
2016 was a year of comprehensive promotion of deepening reforms in the pharmaceutical, medical, and healthcare industries. In previous years, the national level policies for the pharmaceutical, medical, and healthcare industries were mainly implemented by the National Health and Family Planning Commission CFDA、 The Ministry of Commerce, the National Development and Reform Commission, and other departments send industry documents, but 2016 is the opening year of the "13th Five Year Plan for Medical Reform", which is a work that the State Council needs to attach importance to. Therefore, accelerating the process of medical reform has become an important task.
　　
　Sixteen major changes that will occur in 2016:
　　
There are numerous policies and issues regarding the quality standards of drugs, and in the future, China's drug quality standards will be elevated to a significant level;
　　
2. The regulation of the pharmaceutical industry continues to strengthen. In 2016, more pharmaceutical companies will have their relevant certificates or qualifications revoked by GMP and GSP flight inspections than in 2015;
　　
The strengthening of the bidding system and the comprehensive promotion of secondary bargaining have led to a decrease in the profit margins of pharmaceutical companies;
　　
4. The implementation of the new advertising law has caused many enterprises that rely on traditional media to suffer, and they have temporarily lost their basic business models;
　　
5. Policies such as the proportion of drugs, graded diagnosis and treatment, and cost control will gradually lead to a decrease in the use of drugs in medical institutions, while the sales of prescription drugs outside of hospitals will gradually strengthen;
　　
6. The behavior of commercial bribery has not been fundamentally curbed, but it is more secretive, and many have begun to put on the cloak of academic promotion;
　　
7. Experimental policies for online prescription drugs will be introduced in 2016, but the competition in the online prescription drug market will directly enter a white hot stage.
　　
8. The business models of pharmaceutical and health product companies have split, and companies that only sell products or advertise are gradually shifting towards consumer demand, bringing more value-added services to consumers and encouraging everyone to participate in big health. However, more of them are blindly following the trend.
　　
9. The industry's risk warning line is rising, many receivables are increasing, profits are decreasing, competition is intensifying, and inertia business and marketing models are gradually losing their support points. Enterprises are being forced to accelerate their transformation behavior.
　　
10. The trend is to lower the prices of drugs, equipment, consumables, and other products through bidding agencies, rather than raising the prices of many drugs, household appliances, and other products from non-public medical institutions. The water content of many products included in the bidding catalog is gradually being squeezed, especially the Sanming model, which will cause a major shock in the pharmaceutical and medical industries once it is fully opened up nationwide.
　　
11. Medical registration will be accelerated, and "fake new drug registration" through modifications to dosage forms, packaging, and specifications will be curbed;
　　
The cooperation between foreign pharmaceutical companies and domestic pharmaceutical companies will rapidly expand, and Chinese pharmaceutical companies that are good at seizing opportunities will have more development opportunities than obtaining first generic drugs through research and development, and will build a stronger business pattern through various platform cooperation models;
　　
13. Chinese medicine and traditional Chinese medicine will have great development opportunities, and a large number of traditional Chinese medicine clinics will emerge. Pharmaceutical companies that layout traditional Chinese medicine and traditional Chinese medicine will benefit greatly;
　　
The primary healthcare market will become a battleground for Chinese pharmaceutical companies;
　　
15. The diversification process of pharmaceutical companies is accelerating, and more pharmaceutical companies will face the dilemma of diversification.
　　
16. The transformation of pharmaceutical companies has become a forced choice, but many pharmaceutical companies have experienced a significant decline in performance in 2016 due to the inability to find a suitable transformation path, either gradually sinking, seeking medical treatment in a panic, or waiting and watching. And some pharmaceutical enterprises that have a good vision and a long view and started to transform in the past few years will have a Dafengshou (Salad of assorted fresh vegetables) in 2016.